SERINC1 Inhibitors

Chemical inhibitors of SERINC1 disrupt its function through various mechanisms that involve the alteration of the cellular membrane environment where this protein operates. Amiloride, for instance, inhibits the sodium/proton exchanger, leading to intracellular acidification. This environment is less conducive for the proper insertion and functioning of SERINC1 in the plasma membrane. Chlorpromazine has the ability to intercalate into cellular membranes, potentially disrupting microdomains such as lipid rafts, which are crucial for the localization and operation of SERINC1. Similarly, GW4869 inhibits neutral sphingomyelinase, thereby altering the lipid makeup of the cell membrane and potentially preventing SERINC1 from interacting with essential membrane components or domains.

The function of SERINC1 is also inhibited by chemicals that extract or bind to cholesterol within the membrane. Methyl-β-cyclodextrin extracts cholesterol, disrupting the lipid raft architecture required for the optimal functioning of SERINC1. Filipin III, by binding to cholesterol, can also disrupt these rafts and, subsequently, SERINC1's activity. Statins, such as Simvastatin and Lovastatin, inhibit HMG-CoA reductase, reducing cholesterol biosynthesis. With less cholesterol available, the membrane domains that facilitate SERINC1's function become compromised, leading to inhibition. Manumycin A, through its inhibition of farnesyl transferase, alters the prenylation and membrane association of proteins that could be necessary for SERINC1's activity, which results in its functional inhibition. Nystatin, while typically targeting ergosterol in fungal membranes, forms pores in mammalian cell membranes that contain cholesterol, which can disrupt the membrane integrity and inhibit SERINC1. Lastly, compounds like Ro 48-8071 and U18666A that inhibit steps in cholesterol synthesis and trafficking, respectively, would lead to a loss of cholesterol-dependent domains essential for SERINC1, resulting in inhibition of its function.